Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 9/20 | 0.35 |
| ▸ | ABL1 | P00519 | 3/20 | 0.35 |
| ▸ | SRC | P12931 | 3/20 | 0.35 |
| ▸ | FYN | P06241 | 2/20 | 0.35 |
| ▸ | YES1 | P07947 | 2/20 | 0.35 |
| ▸ | RET | P07949 | 2/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.35 |
| ▸ | CDK8 | P49336 | 3/20 | 0.34 |
| ▸ | RICTOR | Q6R327 | 6/20 | 0.34 |
| ▸ | MAPKAP1 | Q9BPZ7 | 6/20 | 0.34 |
| ▸ | MLST8 | Q9BVC4 | 6/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.34 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2473153 | 0.88 | MTOR (0.41) | MTORABL1SRCFYNRET | |
| SCHEMBL2469840 | 0.87 | S1PR1 (0.46) | MTORPIK3CAS1PR1S1PR3LRRK2 | |
| SCHEMBL2473761 | 0.81 | S1PR1 (0.49) | S1PR1S1PR3 | |
| SCHEMBL2831128 | 0.81 | S1PR1 (0.39) | S1PR1S1PR3 | |
| SCHEMBL2474330 | 0.81 | S1PR1 (0.34) | S1PR1S1PR3 | |
| SCHEMBL2470503 | 0.80 | S1PR1 (0.38) | S1PR1S1PR3 | |
| SCHEMBL2473513 | 0.80 | PSMD11 (0.38) | S1PR1S1PR3 | |
| SCHEMBL3463743 | 0.80 | S1PR1 (0.38) | PIK3CDS1PR1S1PR3 | |
| SCHEMBL2472055 | 0.79 | S1PR1 (0.36) | S1PR1S1PR3 | |
| SCHEMBL2472586 | 0.79 | S1PR1 (0.44) | S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2455081-A1 | S1P1 receptor agonists for use in the treatment of crohn's disease | Almirall, S.A. (ES) | 2012-05-23 | — | — | EP | claimed |
| EP-2455080-A1 | S1P1 receptor agonists for use in the treatment of multiple sclerosis | Almirall, S.A. (ES) | 2012-05-23 | — | — | EP | claimed |
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2011-12-22 | — | — | US | claimed |
| EP-2370431-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | Almirall S.A. (ES) | 2011-10-05 | — | — | EP | claimed |
| WO-2010072352-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2010-07-01 | — | — | WO | claimed |
| EP-2455080-A1 | S1P1 receptor agonists for use in the treatment of multiple sclerosis | Almirall, S.A. (ES) | 2012-05-23 | — | — | EP | disclosed |
| EP-2455081-A1 | S1P1 receptor agonists for use in the treatment of crohn's disease | Almirall, S.A. (ES) | 2012-05-23 | — | — | EP | disclosed |
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2011-12-22 | — | — | US | disclosed |
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2011-12-22 | — | — | US | disclosed |
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2011-12-22 | — | — | US | disclosed |
| EP-2370431-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | Almirall S.A. (ES) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010072352-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010072352-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | S1PR1, S1PR2, S1PR3 | MTOR 2736/4885ABL1 2592/4885SRC 2236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.